491 related articles for article (PubMed ID: 30015837)
1. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
[TBL] [Abstract][Full Text] [Related]
2. Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.
Han M; Hu J; Lu P; Cao H; Yu C; Li X; Qian X; Yang X; Yang Y; Han N; Dou D; Zhang F; Ye M; Yang C; Gu Y; Dong H
Cell Death Dis; 2020 Jan; 11(1):43. PubMed ID: 31969559
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer.
Liang Y; Li Y; Song X; Zhang N; Sang Y; Zhang H; Liu Y; Chen B; Zhao W; Wang L; Guo R; Yu Z; Yang Q
Cancer Biol Ther; 2018 Feb; 19(2):120-131. PubMed ID: 29293402
[TBL] [Abstract][Full Text] [Related]
4. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR.
Liu C; Lu C; Yixi L; Hong J; Dong F; Ruan S; Hu T; Zhao X
Breast Cancer Res; 2023 Oct; 25(1):124. PubMed ID: 37848981
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Potential Target Genes of Borneol in Increasing Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer: Bioinformatics and In Vitro Studies.
Lestari IA; Putra IMR; Fatimah N; Ujiantari NSO; Putri DDP; Hermawan A
Asian Pac J Cancer Prev; 2024 May; 25(5):1623-1634. PubMed ID: 38809634
[TBL] [Abstract][Full Text] [Related]
6. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2019 Feb; 26(1-2):1-10. PubMed ID: 29925897
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.
Zhang B; Shi J; Shi X; Xu X; Gao L; Li S; Liu M; Gao M; Jin S; Zhou J; Fan D; Wang F; Ji Z; Bian Z; Song Y; Tian W; Zheng Y; Xu L; Li W
Drug Resist Updat; 2024 May; 74():101068. PubMed ID: 38402670
[TBL] [Abstract][Full Text] [Related]
8. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
Xing F; Gao H; Chen G; Sun L; Sun J; Qiao X; Xue J; Liu C
Mol Cancer; 2023 Jan; 22(1):6. PubMed ID: 36627608
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: A pilot study.
Wang J; Xu R; Yuan H; Zhang Y; Cheng S
Medicine (Baltimore); 2019 Jun; 98(26):e15872. PubMed ID: 31261495
[TBL] [Abstract][Full Text] [Related]
10. The functional roles of exosomal long non-coding RNAs in cancer.
Wang M; Zhou L; Yu F; Zhang Y; Li P; Wang K
Cell Mol Life Sci; 2019 Jun; 76(11):2059-2076. PubMed ID: 30683984
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
Burguin A; Furrer D; Ouellette G; Jacob S; Diorio C; Durocher F
PLoS One; 2020; 15(6):e0234991. PubMed ID: 32584853
[TBL] [Abstract][Full Text] [Related]
12. Deep learning-assisted monitoring of trastuzumab efficacy in HER2-Overexpressing breast cancer via SERS immunoassays of tumor-derived urinary exosomal biomarkers.
Kim J; Son HY; Lee S; Rho HW; Kim R; Jeong H; Park C; Mun B; Moon Y; Jeong E; Lim EK; Haam S
Biosens Bioelectron; 2024 Aug; 258():116347. PubMed ID: 38723332
[TBL] [Abstract][Full Text] [Related]
13. Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer.
Duan N; Hua Y; Yan X; He Y; Zeng T; Gong J; Fu Z; Li W; Yin Y
Adv Sci (Weinh); 2024 May; 11(18):e2309424. PubMed ID: 38460162
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer-derived exosomal lncRNA SNHG14 induces normal fibroblast activation to cancer-associated fibroblasts via the EBF1/FAM171A1 axis.
Dong H; Yang C; Chen X; Sun H; He X; Wang W
Breast Cancer; 2023 Nov; 30(6):1028-1040. PubMed ID: 37653187
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated trastuzumab delivery to the central nervous system for human epidermal growth factor receptor 2+ brain metastasis.
Werner MS; Aras S; Morgan AR; Roamer J; Param NJ; Olagbegi K; Lamontagne RJ; Greig JA; Wilson JM
Cancer Gene Ther; 2024 May; 31(5):766-777. PubMed ID: 38480976
[TBL] [Abstract][Full Text] [Related]
16. Increasing circulating exosomes-carrying TRPC5 predicts chemoresistance in metastatic breast cancer patients.
Wang T; Ning K; Lu TX; Sun X; Jin L; Qi X; Jin J; Hua D
Cancer Sci; 2017 Mar; 108(3):448-454. PubMed ID: 28032400
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA.
Ahmadpour ST; Orre C; Bertevello PS; Mirebeau-Prunier D; Dumas JF; Desquiret-Dumas V
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958880
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo.
Kuchukulla RR; Hwang I; Kim SH; Kye Y; Park N; Cha H; Moon S; Chung HW; Lee C; Kong G; Hur W
Eur J Med Chem; 2024 Jan; 264():116014. PubMed ID: 38061230
[TBL] [Abstract][Full Text] [Related]
19. Molecular Detection and Analysis of Exosomes Using Surface-Enhanced Raman Scattering Gold Nanorods and a Miniaturized Device.
Kwizera EA; O'Connor R; Vinduska V; Williams M; Butch ER; Snyder SE; Chen X; Huang X
Theranostics; 2018; 8(10):2722-2738. PubMed ID: 29774071
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNAs in anti-cancer drug resistance.
Chen QN; Wei CC; Wang ZX; Sun M
Oncotarget; 2017 Jan; 8(1):1925-1936. PubMed ID: 27713133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
